Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Deucravacitinib (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms RePhlect
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 03 Feb 2025 Planned End Date changed from 31 Dec 2028 to 30 Apr 2028.
- 03 Feb 2025 Planned primary completion date changed from 31 Jul 2028 to 30 Apr 2028.
- 03 Feb 2025 Status changed from not yet recruiting to recruiting.